Curt Christoffersen
Pfizer (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Neurotransmitter Receptor Influence on Behavior, Neuroscience and Neuropharmacology Research, Cholinesterase and Neurodegenerative Diseases, Computational Drug Discovery Methods
Most-Cited Works
- → Evidence for N-methyl-d-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: Possible preferential role for N-methyl-d-aspartate receptors(1995)112 cited
- → Modulation of dopamine neuronal activity by glutamate receptor subtypes(1997)90 cited
- → Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo(2012)79 cited
- → Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors(2012)60 cited
- → Metabotropic glutamate receptor-mediated inhibition and excitation of substantia nigra dopamine neurons(1997)33 cited
- → Adverse effects of a SERM (Levormeloxifene)(2003)32 cited
- → Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats(2009)24 cited
- → P2‐240: PF‐04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non‐clinical species to healthy human volunteers(2009)24 cited
- → CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.(1995)15 cited
- → Lack of involvement of haloperidol-sensitive sigma binding sites in modulation of dopamine neuronal activity and induction of dystonias by antipsychotic drugs(1992)13 cited